Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
News|Videos|July 29, 2023
Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC
Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.
Advertisement
Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the updated survival results of the phase 3 ADAURA trial (NCT02511106) in resectable EGFR-mutant non–small cell lung cancer.
Advertisement
Related to this article
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
3
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
4
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
5